Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
ABSTRACT Zika virus caught the world by surprise by its rapid spread and frightening disease outcomes. This major epidemic motivated many scientists to focus their attention on controlling this emerging pathogen. As many as 45 vaccine candidates are being developed, but progress in the antiviral are...
Guardado en:
Autores principales: | Devika Sirohi, Richard J. Kuhn |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/087799d59f7b43c6a462dc9d8246d579 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
<italic toggle="yes">N</italic>-Methyl-<sc>d</sc>-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by Zika Virus Infection
por: Vivian V. Costa, et al.
Publicado: (2017) -
Zika Virus Infection and Colorectal Involvement
por: Viroj Wiwanitkit
Publicado: (2019) -
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
por: Stuart J Thomas, et al.
Publicado: (2009) -
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade AG, et al.
Publicado: (2014) -
A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity
por: Jasmine Moshiri, et al.
Publicado: (2020)